DRUG
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
Status
Completed
Phase
Phase 3
Enrollment
1,054
Locations
155
Results
Posted
Publications
3
Study summary
What the protocol is testing.
This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.
Full detailed description
This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy. Screening/Baseline: Patients will undergo an up to 28-day Screening/Baseline period to allow for any necessary diagnostic procedures, allow for required washout of medications and to determine study eligibility. If otherwise eligible based on screening criteria, patients will undergo a 2-week baseline assessment using an electronic diary where they will record daily assessments of bowel movements (BMs), stool consistency (Bristol Stool Form Scale-BSFS), abdominal pain and other IBS-related symptoms. Data from the two-week electronic diary assessment just prior to the randomization visit will be used to confirm IBS-C and study eligibility as well as define the patient's baseline from which change will be determined. Treatment: Patients who meet all entry criteria will be randomized (1:1:1) to one of three blinded treatment groups on Day 1 of the Treatment period. Patients will take an oral dose of study drug OD for 12 weeks and continue the daily electronic diaries (BMs, rescue medication use, abdominal pain, and other symptoms). During treatment weeks 4, 8, and 12, patients will return to the clinic to undergo safety and efficacy assessments. Post-Treatment: For 2 weeks after completing dosing, patients will continue to complete daily electronic diaries. Patients will then return to the clinical site for a final follow-up visit during Week 14 following randomization. The planned duration of participation in this study will be at least 116 days from signing of informed consent through post-treatment or up to approximately 135 days with visit windows considered.
Interventions
Treatment arms and agents.
DRUG
Placebo
Timeline
From registration to results.
First posted
Mar 13, 2015
Study start
Dec 2014
Primary completion
Dec 2016
Study completion
Feb 2017
Results posted
Jun 14, 2019
Registry updated
Jun 14, 2019
Outcomes
What the study measures.
Primary outcomes
Number of Overall Responders - ITT Population
Time frame · 12 Weeks
An Overall Responder was a patient who was a Weekly Responder (i.e., decrease of 30% from baseline for abdominal pain intensity and an increase of at least one complete spontaneous bowel movement in the same week) for at least 6 of the 12 treatment weeks.
Number of Abdominal Pain Responders for at Least 6 of 12 Treatment Weeks
Time frame · 12 Weeks
An Abdominal Pain Intensity Responder was a patient who had a decrease of 30% from baseline for abdominal pain intensity. Baseline was the mean of non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.
Number of Stool Frequency Responder for at Least 6 of the 12 Treatment Weeks
Time frame · 12 weeks
A Stool Frequency Responder is defined as a patient who experienced an increase of at least one CSBM (complete spontaneous bowel movement) per week from baseline. Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.
Secondary outcomes
Number of Sustained Efficacy Responders
Time frame · 12 weeks
A Sustained Efficacy Responder was a patient who was an Overall Responder who also was a Weekly Responder, i.e., decreased of 30% from baseline for abdominal pain intensity and increased of at least one CSBM (complete spontaneous bowel movement) in the same week for at least 2 of the 4 weeks in month 3 of the Treatment Period.
Change From Baseline in Stool Consistency
Time frame · Baseline and 12-Week
Change from baseline in stool consistency based upon the Bristol Stool Form Scale (BSFS) Rating 1 to 7. Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. BSFS Rating 1 to 7: 1. Separate hard lumps, like nuts (hard to pass) 2. Sausage-shaped but lumpy 3. Like a sausage but with cracks on its surface 4. Like a sausage or snake, smooth and soft 5. Soft blobs with clear-cut edges (passed easily) 6. Fluffy pieces with ragged edges, a mushy stool 7. Watery, no solid pieces, entirely liquid
Change From Baseline in Straining
Time frame · Baseline and 12-week
Change from baseline in Straining Score over the 12-week treatment period. Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The severity of straining during a bowel movement was measured using an 11-point scale (0-10 rating; 0 = no straining; 10 = worst straining).
Change From Baseline in CSBM Frequency Rate
Time frame · Baseline and 12-Week
Change from baseline over the 12-week Treatment Period in CSBM (Complete Spontaneous Bowel Movement) Frequency Rate (CSBMs/Week). Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.
Number of Patients With a SBM Within 24 Hours After the First Dose
Time frame · Up to 24 hours after first dose of study drug
Number of patients with a SBM (spontaneous bowel movement) within 24 hours after the first dose of study drug
Change From Baseline in Abdominal Pain
Time frame · Baseline and 12-Week
Change from baseline in abdominal pain as measured with an 11-point (0-10) Numerical Rating Scale from 0 (No) to 10 (Worst Possible). Baseline is the mean of non-missing abdominal pain scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 85 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: •Adult patients between the ages of 18 and 85 years (inclusive) with a diagnosis of IBS based on ROME III diagnostic criteria and meeting criteria for diagnosis of the constipation predominant subtype - IBS-C Exclusion Criteria: * Refusal or inability to sign informed consent for the trial * Refusal or inability to complete daily Episodic (real-time) BM / RM calls, End of Day daily Calls, and/or complete electronic questionnaires * BMI \> 35 or \< 18 * Women of child bearing potential who refuse to use an acceptable method of birth control for the duration of the trial * Women who are pregnant or lactating * Diagnosis of IBS-D or IBS-M * Organic or obstructive disease of the small or large intestine * Use of laxatives other than the study-supplied rescue medication (Dulcolax®, bisacodyl) * Use of a prohibited concomitant medication within the time frame prior to screening outlined in the study protocol for that medication * Unstable medical illness * Bilirubin \> 3X ULN in the absence of a conjugation defect * Any laboratory value \> 3X ULN unless discussed and approved by the study Medical Monitor
Study locations
155 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Synergy Research Site
Athens, Alabama, United States
Synergy Research Site
Birmingham, Alabama, United States
Synergy Research Site
Dothan, Alabama, United States
Synergy Research Site
Foley, Alabama, United States
Synergy Research Site
Huntsville, Alabama, United States
Synergy Research Site
Montgomery, Alabama, United States
Synergy Research Site
Chandler, Arizona, United States
Synergy Research Site
Glendale, Arizona, United States
Synergy Research Site
Phoenix, Arizona, United States
Synergy Research Site
Tucson, Arizona, United States
Synergy Research Site
Tucson, Arizona, United States
Synergy Research Site
Conway, Arkansas, United States
Synergy Research Site
Little Rock, Arkansas, United States
Synergy Research Site
Little Rock, Arkansas, United States
Synergy Research Site
Anaheim, California, United States
Synergy Research Site
Artesia, California, United States
Synergy Research Site
Chula Vista, California, United States
Synergy Research Site
Corona, California, United States
Synergy Research Site
Encino, California, United States
Synergy Research Site
Fountain Valley, California, United States
Synergy Research Site
Fresno, California, United States
Synergy Research Site
Garden Grove, California, United States
Synergy Research Site
La Mesa, California, United States
Synergy Research Site
La Mirada, California, United States
Publications
Results and literature.
Related trials
More studies on Plecanatide.
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent Participants 6 to Less Than 18 Years of Age With FC
Bausch Health Americas, Inc. · Functional Constipation (FC)
Phase 2
Active, not recruiting
180
2026-07
GCC Agonist Signal in the Small Intestine
University of Wisconsin, Madison · Barrett Esophagus · Gastroesophageal Reflux Disease
Phase 1
Completed
43
2026-04
Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)
Bausch Health Americas, Inc. · Irritable Bowel Syndrome With Constipation
Phase 2
Completed
218
2025-12
Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional Constipation
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · Functional Constipation
Phase 3
Completed
648
2024-07
Long Term Safety Study of Plecanatide
Bausch Health Americas, Inc. · Irritable Bowel Syndrome
Phase 3
Completed
2,272
2020-08
SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation
Bausch Health Americas, Inc. · Chronic Idiopathic Constipation
Phase 2
Completed
84
2020-01
12-Week Study of Plecanatide for CIC (The CIC3 Study)
Bausch Health Americas, Inc. · Chronic Idiopathic Constipation
Phase 3
Completed
1,394
2019-12
A Postmarketing Study of Plecanatide in Breast Milk of Lactating Women Treated With TRULANCE®
Bausch Health Americas, Inc. · Chronic Idiopathic Constipation
Not applicable
Completed
7
2019-11
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.